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Two novel probes reveal tubular and vascular Arg-Gly-Asp (RGD)
binding sites in the ischemic rat kidney. We have previously demonstrated
that RGD peptides prevent tubular obstruction in ischemic acute renal
failure (ARF) and suggested that exposed unoccupied integrin receptors
represent the target for such therapy. The present study investigated the
topography of RGD binding sites and integrin receptors in ischemic rat
kidneys. Two RGD peptides were synthesized: a cyclic biotinylated (Bt)
RGD peptide and a linear RGD peptide (GRGDSP) labeled with
rhodamine green (RhoG). Rats were subjected to 45 minutes of renal
artery occlusion, kidneys were harvested at different times post-ischemia,
and stained with RGD peptides and a panel of antibodies to integrins. In
control, Bt-RGD staining was undetectable in alkaline phosphatase
histochemistry, whereas immunofluorescence detection with Rho-strepta-
vidin conjugate as well as RhoG-GRGDSP staining faintly decorated the
basolateral aspect of the proximal tubular cells in a punctate fashion. In
contrast, ischemic kidneys showed binding to the basolateral and apical
aspects of proximal tubules, peritubular capillaries, and desquamated cells
within tubular lumen. The most conspicuous staining of ischemic kidneys
was obtained with antibodies to the /31 (labeling of the apical aspect of
proximal and distal tubules, as well as desquamated cells obstructing
tubular lumen) and the aV (glomeruli, tubular epithelia, intima of blood
vessels stained faintly, while the obstructing cellular conglomerates
showed intense staining) subunits. Double staining with Bt-RGD and
antibodies against the /31 and csV/33 integrins showed co-localization of
staining within the tubules and vasculature, respectively. In Vitro attach-
ment of HL-60 leukocytes to the endothelial cells was inhibited by the
cyclic RGD peptide. In conclusion, expression of RGD binding sites and
j31 integrin subunits along the apical aspect of tubular epithelia and on the
surface of desquamated cells is in concert with the hypothesis on the
pathogenetic role of RGD-recognizing integrins in tubular obstruction.
The expression of RGD binding sites along the intimal surface of blood
vessels in ischemic kidneys suggests an additional target for RGD peptides
in vascular endothelial cells.
Renal tubular obstruction represents an important pathophys-
iological mechanism for perpetuation of oliguria and renal dys-
function in acute renal failure (ARF) [1—4]. The pathogenesis of
tubular obstruction in ARF has recently received renewed atten-
tion. Studies in experimental animals with ARF and in humans
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with this syndrome have demonstrated that viable renal tubular
epithelial cells are abundantly present in the urine [5, 6]. One
implication of this finding is that non-lethally damaged epithelial
cells, rather than necrotic debris, undergo detachment from the
basement membrane, and potentially may become a nidus for
developing tubular obstruction [5, 7, 8]. Based on the previous in
vitro findings of the loss of integrins from the basal cell surface and
their appearance on the apical side [9], we have postulated that
desquamated cells attach to each other or to the cells remaining in
situ via integrin receptors recognizing the RGD sequence. Further
studies have shown that infusion of RGD peptide immediately
after the release of the renal artery clamp in a rat model of renal
ischemia virtually abolished the characteristic elevation in proxi-
mal tubular pressure, used as an indicator of tubular obstruction
[10], and that systemic administration of cyclic RGD peptides to
rats with ischemic ARF attenuated renal dysfunction and accel-
erated recovery of renal function [11]. Most recently, we have
characterized tissue distribution and clearance of 99mTcRGD
peptide [121. These studies demonstrated that the labeled peptide
is retained by ischemic kidneys. The above observations, although
consistent with the proposed model of tubular obstruction via the
integrin-dependent RGD-sensitive conglomeration of desqua-
mated epithelial cells, were lacking in the precise localization of
RGD binding sites within the kidney. Therefore, we sought to
perform a histological mapping of RGD binding sites in intact and
ischemic kidneys. Experiments conducted with two novel synthetic
fluorophore-labeled RGD peptides and the localization of RGD
binding Sites in ischemic rat kidneys are presented below.
METHODS
Antibodies, cell culture and other chemicals
Four different antibodies against the /31 integrin subunit were
used in this work; polyclonal AB 1938 were obtained from
Chcmicon mt. (Temecula, CA, USA), and monoclonal DF5 were
also from Chemicon mt. P4C1O were purchased from Life Tech-
nologies (Gaithesburg, MD, USA) and 4B4 from Coulter Immu-
nology (Hialeah, FL, USA). Polyclonal antibodies specific for csV
(AB 1930), /33 (AB 1932), cs5 (AB 1928) and /34 (AB 1922)
subunits as well as monoclonal against /32 (P4H4) subunit and
vitronectin receptor aV/33 were obtained from Chemicon mt.
Cultures of MDCK cells were obtained from ATCC (Rockville,
MD, USA) and were maintained according to the supplier
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instructions. Linear peptides were purchased from Bachem (Tor-
rance, CA, USA), rhodamine green TFA, succinimidyl ester was
obtained from Molecular Probes (Eugene, OR, USA).
Synthesis and validation of a biotinylated cyclic RGD peptide
The pentapeptide RGDfK was synthesized by the Merrifield
solid-phase method using o-chlorotritylchloride resin with a 9-flu-
orenylmethoxycarbonyl strategy in N,N'-dimethylformamide [13—
151. The side chain of aspartic acid (D) was protected as tertbutyl
ester. 4-Methoxy-2,3,6-trimethylbenzenesulfonyl (Mtr) served as
protection of the guanidinofunction of arginine (R) and benzyl-
oxycarbonyl (Z) as protection of the K e-aminofunction. All
amino acids were coupled with 1/1.5 eq. 2-(1H-benzotriazol-1-yl)-
1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU)/1-hydroxy-
benzotriazole (HOBt) in 1-methyl-2-pyrrolidinone. As basic
component served N,N-diisopropylethylamine (DIPEA). Depro-
tection of the N-terminal 9-fluorenylmethoxycarbonyl protecting
groups was performed with 20% piperidine in N,N'-dimethylfor-
mamide. For cleavage from the resin a mixture of acetic acid!
2,2,2-trifluoroethanol/dichioromethane (1:1:8) was used. The cy-
clization was achieved with 3 Eq diphenylphosphorylazide
(DPPA) in N,N'-dimethylformamide over 24 hours with 5 Eq
sodium bicarbonate as solid base.
Biotinylation was performed after selective hydrogenolysis of
the K side chain benzyloxycarbonyl protecting group with 10%
palladium on charcoal in methanol over seven hours. Biotin-€-
aminohexanoic acid (Bt-eAhx) was coupled with N-ethyl-N'-(3-
dimethylaminopropyl)-carbodiimide (EDCI) in N,N' -dimethyl-
formamide. Biotin-€-aminohexanoic acid was synthesized from
e-aminohexanoic acid and biotin, activated as N-hydroxysuccin-
imide ester in N,N'-dimethylformamide. After coupling, the re-
maining side chain protection groups were cleaved in strong acidic
medium, with trifluoroacetic acid/distilled water/1,2-ethanedithi-
ole (90:5:5).
Final purification of the crude peptide was performed by
reversed-phase high performance liquid chromatography (RP-
HPLC) using C18-material (semipreparative, Macherey & Nagel,
Nucleosil 100-C18) with a gradient of distilled water/acetonitrile!
trifluorocetic acid (80:20:0.1 to 50:50:0.1) over 30 minutes.
The authenticity of cyclo(RGDf[Bt-eAhx-K]) was confirmed by
HPLC and fast atomic bombered (FAB) mass spectroscopy. The
FAB mass spectrum was recorded on a Varian MAT 311A mass
spectrometer with m/z = 943 for the peptide cyclo(RGDf[Bt-
eAhx-K1) (C42H63N12010S) with a calculated molecular weight of
943.15.
Synthesis and validation of rhodamine-conjugated glycine-
arginine-glycine-aspartic acid-serine-proline (GRGDSP) peptide
The method of conjugation was similar to a previously pub-
lished technique [161. Peptide (4 mg, 6.8 iimol) was dissolved in a
mixture of acetonitrile (50 j.d) and an aqueous solution of sodium
bicarbonate (50 d, 0.2 M; pH = 9.0). A solution of Rhodamine
Green (RhoG) succinimidyl ester (5 mg, 7.5 jrmol) in dimethyl-
formamide (15 tl) was added under nitrogen in the dark. The
reaction mixture was stirred at room temperature overnight. A
fresh aqueous solution of hydroxylamine (50 pA, 1.5 M, pH = 7.8)
was added. After three hours reaction, the mixture was dissolved
in 15% aqueous acetonitrile (4 ml), and products were separated
by HPLC under reversed-phase conditions using semipreparative
YMC-Pack ODS-AM column (300 X 10 mm I.D.) (eluent:
acetonitrile/water/0.05% TFA, 15 to 50% gradient of acetonitrile,
40 mm). The yield was 40%.
Mass spectra of the resultant products were recorded on a
VESTEC laser desorption time-of-flight mass spectrometer. Mass
spectroscopy confirmed the product C43H48N11014 with the cal-
culated molecular wt of 942.92. The product identified as RhoG-
GRGDSP, m/z = 944.3, was used for fluorescence mapping of
RGD binding sites.
Cell attachment inhibition (peptide probes characterization
assay)
To measure MDCK cells attachment to vitonectin and fibronec-
tin MDCK cells were detached by 0.05% Trypsin!0.01% EDTA
solution and Trypsin was immediately inactivated by addition of
twofold access of Trypsin inhibitor in PBS. In 96 well plates 20,000
cells per well were added. Wells were coated with 10 .tg/ml of
vitronectin or fibronectin at 37°C for one hour. After washing with
PBS, the wells were blocked with 1% BSA in PBS for one hour at
37°C. Wells coated with 1% BSA were used to determine the
background adhesion. Peptides and conjugated probes were
added to cell suspension before loading wells. After incubation for
one hour at 37°C unattached cells were washed out and attached
cells were fixed with 2% glutaraldehyde in PBS for 20 minutes.
Fixed cells were stained with 0.1% crystal violet in 0.2 M pH 9.0
boric acid. After solubilization of crystal violet in 10% acetic acid
the absorbance at 590 nm was measured on ELISA plate reader.
All experimental conditions were repeated four times.
Surgical procedures
All experiments were conducted in accordance with the NIH
"Guide for the Care and Use of Laboratory Animals." Sprague-
Dawley male rats weighing 150 to 200 g were housed in cages for
three days at least and allowed chow and water ad libitum. After
an overnight fast, animals were anesthetized with 0.27 ml/100 g
body wt of a cocktail [Ketaset (Aveco Co., JO, USA) 0.6 ml,
Rompun (Mobay Co., Shawnee, KA, USA) 0.2 ml, normal saline
0.6 mlj. The animals were placed on a heated surgical table, and
rectal temperature was maintained at 37°C. A 2.5 cm anterior
midline incision was made, the right kidney was externalized, and
the renal pedicle was under-passed with two 2-0 sutures. The left
kidney was exposed, the renal artery was dissected from the renal
vein and also under-passed with 2-0 suture. Both ends of the
suture were passed through a 1 cm polyethylene cannula. An
intramuscular injection of 250 U/kg heparin was given 15 minutes
before the operation. Renal ischemia was initiated by compressing
the left renal artery. After 45 minutes, the left renal artery was
released. The right renal artery and the right ureter were ligated
and a right nephrectomy was performed. The incision was closed
with 2-0 suture and surgical staples.
Blood was drawn 24 hours after release of the renal artery.
Plasma BUN and Cr in control animals averaged 18.4 1.0 mg/dl
and 0.62 0.02 mg/dl (mean sc), whereas in the 45-minute
ischemic group plasma concentration of BUN and Cr was in-
creased to 67.8 7.5 mg/dl and 1.78 0.43 mg/dl. The database
of this work consisted of three intact, three sham, four ischemic
kidneys stained after fixation, and three ischemic kidneys labeled
in vivo with Bt-RGD, then, after the sacrifice fixed and counter-
stained. Additionally two control and experimental rats were used
for preparation of vascular trees.
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Immunohistochemical techniques
Immunohistochemistry was performed using an indirect immu-
noperoxidase technique. Briefly, endogenous peroxidase activity
was blocked on thawed cryosections by incubation with 1%
hydrogen peroxide in PBS for 20 minutes. Nonspecific binding
sites were saturated by incubation with 5% bovine serum albumin
(BSA) in PBS for 30 minutes. Sections were incubated for 60
minutes with primary antibodies diluted in phosphate-buffered
saline (PBS) with the addition of 0.2% BSA. All the subsequent
steps were performed according to manufacturer's instructions
(Dako LSAB2 kit, Carpinteria, CA, USA). Immunohistochemical
controls included an omittance of first antibodies and exchange of
primary antibodies for normal mouse or rabbit IgG or monoclonal
antispectrin antibodies (Sigma Chemical Co., St. Louis, MO,
USA). Sections were counterstained with Mayer's hematoxylin
and mounted in GelMount (Biomeda, Foster City, CA, USA).
Staining with Bt-RGD was performed after blocking nonspe-
cific binding with 5% BSA in PBS for 30 minutes. Sections were
incubated for 60 minutes with Bt-RGD, washed three times with
PBS for 10 minutes, stained with streptavidin-conjugated alkaline
phosphatase or streptavidin-FITC for 30 minutes, washed three
times with PBS for 10 minutes on a shaker, and mounted in
GelMount for light microscopy. In control experiments the spe-
cific binding was blocked with unconjugated RGD peptide.
In a separate series of experiments, rats were injected system-
ically with 0.2 mgIlOO g Bt-RGD peptide 24 hours after renal
artery cross-clamping or a sham surgery. Animals were sacrificed
15 to 20 minutes later, kidneys were perfusion-fixed and cryo-
sectioned, as described above. Double immunofluorescent stain-
ing was performed with rhodamine-streptavidin (to visualize
Bt-RGD binding sites) and with a panel of antibodies to integrin
receptors, as detailed in the Results section. The secondary
antibodies used for these studies were conjugated to FITC.
Preparations were mounted using SlowFade and examined using
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Fig. 1. Inhibition of MDCK cells attachment to vitronectin and fibronectin by cyclic (A) and linear (C) RGD peptides and their conjugates with biotin
(B) and RhoG (D). Cell adhesion was measured as described in Methods section and presented as percentage of control adhesion (S fibronectin; A
peptides). Data represent the mean SE of 4 wells
Fig. 2. Control (A) and ischemic (B-F) kidney
cryosections stained with Bt-RGD and
streptavidin-alkaline phosphatase, as detailed
in the Methods section. No binding was
detected in glomeruli (G), tubuli or vessels of
control kidney. In contrast, ischemic kidneys
showed Bt-RGD binding to glomeruli on B,
basolateral and apical aspects of proximal
tubules on B, intimal surface of blood vessels
on B and E (arrowheads), peritubular
capillaries on C, desquamated and
conglomerated cells within the tubular lumen
(0) on D and F, and along the vasae rection F.
Magnification x200.
Fig. 3. Control A, B) and ischemic (C', D) kidney cryosections stained with RhoG-GRGDSP. Cortical sections are presented in A and C, medullary
sections are presented in B and D. In control kidneys, fluorescence was confined to the hasolateral aspect of proximal tubular epithelia (P) which showed
a characteristic punctatcd pattern. Fluorescence was undetectable in glomeruli (G), distal tubules (D), or vascular structures (V). In sharp contrast,
ischemic kidneys showed conspicuous staining of detached conglomerated cells obstructing the tubular lumen (0) in both the cortical and medullary
sections, on C and D, respectively, along the apical and basolateral aspects of proximal (P) and, to a lesser degree, distal tubular epithelium (D),
glomeruli (G), and vessels (V), including vasae recti (vr). (Magnification X500).
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Fig. 4. Control (A, B, C) and ischemic (D, E, F) kidney sections stained with Bt-RGD.streptavidin FITC (A, D) and monoclonal antibodies 4B4 against
the 131 integrin subunit (B, C, E, F). Cortical sections presented on A,B,D and E and medular on C and F. In control sections the staining pattern was
very similar to the pattcrn presented on Figure 3 A, B. There was no detectable staining associated with glomeruli (G) using both Bt-RGD and pl(A,B).
Punctated pattern over proximal tubular epithelia (P) was detectable. Ischemia resulted in the appearance of a weak immunoreactivity in glomeruli (G),
diffuse bright staining over tubules (P) and desquamated epithelial cells (0). (Magnification X700).
confocal microscopy. Dual images obtained with the appropriate
dichroic mirrors were color-coded and overlaid to produce a
combined image depicting the colocalization of stainings.
For immunofluorescence studies, the labeling by RhoG-conju-
gated RGD peptides was performed in one step after saturation of
nonspecific binding sites, as described above. As a control, the
saturation of RGD binding sites by unconjugated peptide before
labeling was carried out. Sections were mounted in SloFade
mounting medium and examined under an epifluorescence Ni-
kon-Diaphot microscope.
Preparation of vascular trees
Renal resistance arteries were obtained from two control and
two ischcmic rat kidneys by HCI maceration of the parenchymal
tissue followed by microdissection, as previously described [171,
fixed in 3.7% paraformaldehyde and permeabilized with 0.1%
Triton X-100. After a 30 minute incubation with 5% BSA, vessels
were stained with Bt-RGD, as detailed above, for 60 minutes.
Following three washes with PBS, tissues were stained with 1:400
dilution of the goat anti-mouse streptavidin-IgG conjugated with
alkaline phosphatase for 20 minutes, and developed according to
the manufacturer's instructions (Dako LSAB2 kit, Dako Fast
Red). Vascular fragments were extensively washed, mounted on
cover slips with GelMount, and examined with a Nikon Diaphot
microscope.
Effects of RGD peptide on leukocyte-endothelial cell interactions
To examine the possible effect of RGD peptides on leukocyte-
endothelial cell interaction, confluent cultures of human umbilical
vein endothelial cells (HUVEC) were co-incubated with sus-
pended HL-60 cells. HUVEC were isolated and cultured accord-
ing to the technique described by Jaffe et al [181. Cells were
validated by the characteristic cobblestone appearance and ex-
pression of von Willebrand factor, and used between passages 4 to
6. Prior to co-incubation HL-60 cells were labeled with a fixative-
resistant cell-tracer fluorescent probe 5 -chloromethylfluorescein
diacetate. When indicated, HUVEC were initially incubated in an
atmosphere of reduced P°2 (30 torr) for 30 minutes. Suspension
of HL-60 cells (106 cells/mI) was co-incubated with HUVEC
monolayers for 60 minutes on a rocking platform in an incubator
at 37°C in the presence or absence of 10 tM cyclic RGD
pentapeptide RGDfV. After washing with phosphate-buffered
saline and fixation with 4% paraformaldehyde, four io .tm [21
areas were examined under a fluorescence microscope to count
the adherent HL-60 cells. The viability of HUVEC exposed to
hypoxia was not affected during the time course of these experi-
ments, as judged by the results of a parallel staining of cells with
a vital fluorescence indicator calcein acetomethylester. All exper-
iments were performed in triplicate using three different prepa-
rations of HUVEC.
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RESULTS
Characterization of peptide conjugates
The interactions of MDCK cells with vitronectin and fibronec-
tin were inhibited by both peptides in time (data not shown) and
concentration dependent manner (Fig. 1). Inhibition of the at-
tachment to both extracellular matrix proteins by> 75% had been
achieved by 30 tg/ml of cyclic peptide and its biotinylated derivate
(Fig. 1 A, B). The concentration of RhoG probe of GRGDSP was
difficult to calculate precisely, but used dilutions provided the
concentrations close to concentrations of unconjugated peptide.
The dynamic of attachment inhibition was similar in case of
GRGDSP and fluorescent conjugate (Fig. 1 C, D).
Distribution of RGD binding sites
In control kidneys obtained from either intact rats or rats
subjected to sham-operation (laparotomy), Bt-RGD peptide (10
to 50 .tM) produced minimal staining of nephron segments, when
histochemical alkaline phosphatase staining had been used (Fig.
2A). Fluorescence labeling of bound Bt-RGD as well as RhoG-
RGD (50 .LM) staining showed the following distribution (Fig. 3
A, B, and Fig. 4A). Proximal tubular epithelial cells were deco-
rated with RGD peptide, at the basolateral aspect, in a punctated
pattern. The binding of RGD peptide was undetectable in vascu-
lature, glomeruli, and distal tubules. In contrast, ischemic kidneys
demonstrated various degrees of labeling in all these structures.
Basolateral surface of proximal tubules, apical aspect of proximal
tubular cells, desquamating or desquamated cells within the
lumen of proximal and distal tubules, as well as loops of Henle
and vasae recta were intensely labeled with Bt-RGD and RhoG-
RGD peptides (Figs. 2, 3 and 4). Desquamated cellular conglom-
erates impacting tubular lumen, as well as amorphous casts
displayed conspicuous staining. Majority of arcuate, interlobular
and afferent arterioles showed staining with Bt-RGD and RhoG-
RGD peptides along the intimal aspect. However, occasional
labeling was observed in adventitia alone, or on the intimal
surface of blood vessels that were surrounded by impacted tubules
(Fig. 3C).
Expression of integrins
Several classes of integrins could have contributed to the
observed RGD binding pattern [19—21]. Therefore, we next
performed immunocytochemical staining of kidneys with a panel
of antibodies against several relevant subunits of integrin recep-
tors (the /31, /33, /34, and aV). The most conspicuous labeling of
ischemic kidneys was observed with antibodies to /31 and aV
subunits. Control kidneys labeled with /31 antibodies showed the
pattern very similar to the labeling with both peptides (Fig. 4 B,
C). The label localized along the muscular and advential, but not
the intimal, layer of different caliber blood vessels, and showed a
faint staining at the basolateral, but not the apical, aspect of the
proximal and distal tubules, and loops of Henle (data not shown).
Ischemic kidneys displayed, in addition to the above sites, much
more prominent glomerular staining, and were characterized by
various degrees of labeling along the apical aspect of the proximal
and distal tubules, as well as intense staining of desquamated cells
and cellular conglomerates obstructing tubular lumen (Fig. 4 E,
F). Staining of the intima of blood vessels was inconspicuous.
While control kidneys showed minimal staining with antibodies to
the a3 subunit, ischemic kidneys were characterized by the
staining topography that was similar, although less intense, to that
of /31 subunit distribution (data not shown). Antibodies to the aV
subunit mapped the medial layer of blood vessels and faintly
labeled the basolateral aspect of the proximal and distal tubules in
control kidneys. Glomeruli, tubular epithelium, and intima of
blood vessels of ischemic kidneys were faintly stained with the
anti-aV antibody, while the obstructing cellular conglomerates
showed an intense labeling (see below).
In experiments with dual labeling (Bt-RGD injected in vivo and
integrin receptors stained after sectioning and fixation), the
following data were obtained (Fig. 5). In contrast to the incon-
spicuous labeling of control sections with either Bt-RGD or aVf33
antibodies (Fig. 5A), ischemic kidneys showed enhanced labeling
of some conglomerated cells within the tubular lumen and intima
of arterioles (Fig. 5 B, C). Labels colocalized at these sites,
whereas the medullary structures showed a dissociation of staining
for Bt-RGD and aV/33 (Fig. 5D). Dual labeling with Bt-RGD and
antibodies to the /31 subunit of integrins revealed the colocaliza-
tion of these markers in the detached and conglomerated epithe-
hal cells (Fig. SE). There was no consistent colocalization of
Bt-RGD with /33 or aS integrin subunits in the detached and/or
conglomerated epithelial cells (data not shown). These findings
suggest that the binding sites for RGD peptide are represented by
the aV/33 integrin in the vasculature and some desquamated cells,
whereas the majority of the desquamated cells bind Bt-RGD via
/31 integrins.
Staining of vascular trees
To gain further insight into the distribution of RGD binding
sites along the ischemic blood vessels, vascular trees were pre-
pared from control and experimental kidneys and stained with
Bt-RGD. As evident from Figure 6A, control resistance arteries
showed no detectable binding of Bt-RGD, whereas ischemic
vessels (Fig. 6B) were stained with this ligand in a patchy fashion
(occasional vessels are out of focus due to the thickness of
vascular tree preparations).
Effect of cyclic RGD pentapeptide on leukocyte-endothelial cell
adhesion
In view of the above data demonstrating RGD binding sites
along the intimal surface of blood vessels in ischemic kidneys,
these findings were further tested using cultured endothelial cells
co-incubated with leukocytes. Coincubation of HUVEC monolay-
ers with suspension of HL-60 cells resulted in occasional attach-
ment of leukocytes to the endothehium, as illustrated in Figure 7A.
Exposure of HUVEC to 30 minutes of hypoxia led to the doubling
of the number of adhered leukocytes (Fig. 7B). When coincuba-
tion experiments were performed in the presence of 10 LM cyclic
RGD pentapeptide, the adhesion of HL-60 cells to both control
and hypoxic endothelial monolayers was significantly reduced.
DISCUSSION
The studies presented herein utilized two novel fluorescently
labeled RGD peptides to map the binding sites within ischemic
kidneys. Both peptides conserved their binding ability after con-
jugation and therefore could be used in labeling experiments.
RGD probes successfully mapped desquamated and desquamat-
ing epithelial cells within the tubular lumen, as well as the intimal
surface of vessels in ischemic kidneys. Dual labeling experiments
J
Fig. 6. Vascular 'trees' obtained from control (A) and ischemic (B) kidneys
and stained with Bt-RGD. Renal vasculature was prepared as described in
Methods and stained with the indicated probes. Note that control vessels
show faint staining, whereas the vessels obtained from ischemic kidneys were
stained with the Bt-RGD probe (magnification XiOO).
Fig. 5. Dual fluorescence labeling with Bt-RGD
and antibodies to integrin receptors. Bt-RGD
was injected systemically to rats 24 hours after
renal artery cross-clamping. RGD binding sites
were visualized using rhodamine streptavidin.
Colocalization of these sites with various
integrins was examined by indirect
immunofluorescence using FITC-conjugated
IgO. Each panel represents (from left to right)
consecutive images of FITC fluorescence,
rhodamine fluorescence, combined
FITC/rhodamine fluorescence, and transmitted
light images. A. Control staining with antibodies
to oV/33 (green) and rhodamine-streptavidin,
for Bt-RGD (red), and the combined image.
Glomeruli(g). Note the background
fluorescence without any detectable sites of
accumulation for either label, including the
intimal surface of blood vessels (lower left
corner). B—D. Staining of ischemic kidneys with
antibodies to aV/33 (green) and rhodamine-
streptavidin, for Bt-RGD (red). Note the
staining of intimal surface of a blood vessel
with both markers (B) and colocalization of
labeling in some, but not all, detached or
conglomerated cells (o) on C and D. E.
Staining of ischemic kidneys with antibodies to
j31 integrin (green) and rhodamine-streptavidin,
for Bt-RGD (red). Note colocalization of
staining in detached and conglomerating cells.
demonstrated that in the tubules ROD binding sites co-localize
with the i integrins, whereas the binding sites within the vessels
coincide with the aV3 receptors. While the tubular findings are
in concert with our hypothesis on the role of RGD-recognizing
integrins in development of tubular obstruction in renal ischemia,
the discovery of RGD binding sites along the intimal surface of
ischemic blood vessels represents a novel observation.
RGD sequence is the most common motif contained in a
variety of matrix proteins and serving as the recognition site for
diverse integrin receptors [18—20]. Matrix proteins containing this
particular or a related sequence include fibronectin, vitronectin,
laminin, thrornbospondin, tenascin, von Willebrand factor, os-
Fig. 8. Schematic summary of RGD binding sites in the ischemic rat kidney.
Specialized structures along the nephron are magnified to denote RGD
binding Sites on the intimal surface of resistance arteries (A), immunodetect-
able 131 subunits in the proximal nephron on the surface of desquamating or
desquamated cells (B), and ROD binding sites on the surface of epithelial cell
and cellular debris impacting the loop of Henle (C).
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Fig. 7. Effect of cyclic RGD peptide on the adhesion of HL-60 cells to endothelial cells. Adhesion assay was performed as detailed in the Methods
section. HUVEC were used at confluence, HL-60 cells were added to monolayer as suspension and co-incubated during 60 minutes. Adherent HL-60
cells were counted as detailed in the Methods. A. A representative image of adhered HL-60 cells to the endothelial monolayer. B. Adhesion of HL-60
cells to normoxic and hypoxic endothelial cells is inhibited by the RGD peptide. *significant (N = 3, P < 0.05) difference versus control conditions.
teopontin and bone sialoprotein 1 [21—25]. It has recently been
discovered that Zn-2-glycoprotein contains the RGDV sequence
and is abundantly expressed in the proximal and distal tubular
epithelium [261, thus expanding the family of the adhesive RGD-
containing proteins. Integrin receptors that recognize this se-
quence and are relevant to the kidney include the entire cxV
family, a3131, and a5/31 integrins [18, 27, 28], as well as several
other receptors under specific conditions: cs2131 [28] and cs4f3l
[29]. Synthetic RGD peptides have been extensively exploited in
in vitro studies of cell-matrix and cell-cell interactions [10, 30 —321.
There is burgeoning evidence that synthetic RGD peptides
have therapeutic potential in diverse pathological situations.
Several laboratories have explored their potential in preventing
the metastatic spread of B16 melonoma cell line [33, 34] and
demonstrated that RGD peptides significantly reduce the forma-
tion of lung colonies in mice injected with B16 melanoma cells.
These peptides, as well as their natural analogs, disintegrins, have
been also extensively studied as potential antithrombotic agents
which act by inhibiting platelet aggregation [35—38]. Recent
attempts to engineer the molecule of hirudin containing the RGD
sequence and the effect of this chimeric protein on platelet
aggregation have been reported [2]. Synthetic RGD peptides are
also being explored as therapeutics in treatment of osteoporosis
[39]. Previous studies from our laboratory have suggested that
RGD peptides, serving as a decoy, may prevent tubular obstruc-
tion in the ischemic model of acute renal failure [10, 11].
Specifically, we have demonstrated that (1) stressed tubular
epithelial cells reverse the polarity of integrin receptors from the
predominantly basolateral location to the apical cell membrane
[9, 40], as a part of a more generalized process of the loss of
epithelial cell polarity [41, 42]; (2) depletion of integrins expressed
on the basal cell surface leads to the loss of anchorage to the
basement membrane and cell desquamation [9]; (3) expression of
integrin receptors on the apical cell membrane leads to promis-
cuous interactions, such as the adhesion of desquamated cells to
the cells remaining in situ, thus initiating the process of tubular
obstruction [10]; (4) conglomeration of the desquamated cells via
integrin receptors further aggravates tubular obstruction [11].
Importantly, these integrin-based interactions can be blocked by
synthetic RGD peptides. GRGDSP peptide injected into the renal
artery upon release of the renal artery clamp prevented the
elevation of proximal tubular hydrostatic pressure, characteristi-
cally seen in animals with renal ischemia which received injection
of the vehicle or an inactive peptide. In vivo study of RGD
peptides in ischemic ARF in rats demonstrated attenuation of
ARF and accelerated recovery of renal function. Using linear
RGD peptide labeled with Y9fhTc, we have shown that this probe
was retained in isehemic kidneys [12]. To visualize RGD binding
sites at the cellular level, we next elected to perform such a
mapping using fluorescent derivatives of two RGD peptides, a
cyclic Bt-RGD peptide and a linear RhoG-RGD peptide. The
point of using these probes is to visualize unoccupied receptors.
Alternatively, RGD binding can occur upon activation of some
integrins (the best example is provided by the platelet aII/33
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endothelial monolayers, both normoxic arid hypoxic, renders
plausible the above mode of RGD action. In summary, studies
utilizing two dissimilar RGD ligands for fluorescence localization
of RGD binding sites revealed renal tubular binding, as well as the
binding to the resistance vessels. These findings are schematically
presented in Figure 8. While epithelial sites of RGD binding, most
probably to the aV/33 and f31 integrins, have been shown to be
involved in prevention of tubular obstruction [11, 12], a novel
finding of vascular expression of RGD binding sites may shed light
on the pathways of neutrophile infiltration of ischemic kidneys.
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